Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.73 |
| ▸ | ITGAV | P06756 | 20/20 | 0.73 |
| ▸ | ITGB5 | P18084 | 13/20 | 0.68 |
| ▸ | ITGB6 | P18564 | 11/20 | 0.68 |
| ▸ | ITGB8 | P26012 | 11/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7374380 | 0.85 | ITGB3 (0.74) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL7995239 | 0.84 | ITGB3 (1.00) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL10051072 | 0.84 | ITGAV (0.68) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL7980834 | 0.81 | ITGB3 (0.77) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL7376995 | 0.79 | ITGB3 (0.86) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL6420861 | 0.76 | ITGB3 (1.00) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL6422671 | 0.76 | ITGB3 (1.00) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL6420863 | 0.76 | ITGB3 (1.00) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL6422734 | 0.76 | ITGB3 (0.85) | ITGB3ITGAVITGB5ITGB6ITGB8 | |
| SCHEMBL6422730 | 0.76 | ITGB3 (0.85) | ITGB3ITGAVITGB5ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723888-B2 | Polymer conjugated thyrointegrin antagonists | NANOPHARMACEUTICALS LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230181501-A1 | POLYMER CONJUGATED THYROINTEGRIN ANTAGONISTS | NANOPHARMACEUTICALS LLC | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723888-B2 | Polymer conjugated thyrointegrin antagonists | TEK, HDGF, PTGFR | ITGB3 284/4885ITGAV 381/4885ITGB5 478/4885 |
| US-20230181501-A1 | POLYMER CONJUGATED THYROINTEGRIN ANTAGONISTS | TEK, HDGF, PTGFR | ITGB3 284/4885ITGAV 381/4885ITGB5 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.